Mr. Mayes is the Chief Executive Officer and a board member of Antios Therapeutics. Prior to Antios and drawing on inspiration from his son’s epilepsy diagnosis, he raised $40 million from prominent investors and founded the clinical-stage pharmaceutical company, Engage Therapeutics, to develop a product candidate for seizures. Upon approval, Staccato® Alprazolam will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.
Prior to Engage, Mr. Mayes played an integral role in the growth of Advaxis Immunotherapies (NASDAQ: ADXS), a biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its Chief Operating Officer, he was instrumental in helping to secure in excess of $200 million in follow-on funding and developing partnerships with companies such as Amgen, AstraZeneca and Merck & Co.
From 2004 to 2010, Mr. Mayes served as Vice President, General Counsel and Chief Compliance Officer at ImClone Systems Corporation. During his tenure at ImClone, Mr. Mayes supported the clinical development and commercialization of ERBITUX® and contributed significantly to activities that resulted in its acquisition by Eli Lilly for $6.5 billion in 2008.
Mr. Mayes is a cum laude graduate of Syracuse University where he was recognized as a Remembrance Scholar and he earned his J.D. degree magna cum laude from the Temple University School of Law where he was the Articles Editor on the Temple Law Review.
Doug Mayers, MD
Chief Medical Officer
Dr. Mayers is the Chief Medical Officer and a co-founder of Antios Therapeutics. He was most recently Chief Medical Officer at Cocrystal Pharma (NASDAQ: COCP) developing antiviral drugs against Hepatitis B, Hepatitis C and influenza viruses. Notably, in 2007, Dr. Mayers was named Executive Vice President and Chief Medical Officer at Idenix Pharmaceuticals where he was responsible for drug safety and clinical development for therapies targeting HIV, Hepatitis B and Hepatitis C. After Idenix was acquired by Merck Pharmaceuticals (NYSE: MRK) in 2014, he served for a year as a Principal Investigator at the United States Army Medical Research Institute of Infectious Diseases coordinating efforts to develop drugs against Ebola and MERS coronavirus. Dr. Mayers was commissioned into the United States Navy in 1981 and retired after 38 years of service as a Captain, initially serving as a Staff Internist and rising to Department Head, Division of Retrovirology, where he was responsible for directing HIV natural history studies and clinical trials at Army, Navy and Air Force sites domestically. In 1998, Dr. Mayers left Navy active duty to become the Head of the Division of Infectious Diseases at Henry Ford Hospital. He served as Principal Investigator for the NIH-funded clinical trials unit and conducted NIH-funded clinical trials of antiviral drugs and the clinical implications and management of HIV drug resistance. In 2001, he moved to Boehringer Ingelheim Pharmaceuticals as the International Head/Vice President of the Therapeutic Area Virology where he was responsible for the therapeutic area strategy and global clinical development and support for antiviral drugs including Nevirapine and Tipranavir.
Dr. Mayers has served as a consultant to the Food and Drug Administration, as a member of numerous Federal and National Institute of Health committees, study sections, and advisory groups. He has authored numerous publications and is the editor for the two-volume textbook, Antimicrobial Drug Resistance, and is a Fellow of the American College of Physicians and the Infectious Disease Society of America.
He received the Jay P. Sanford Award for lifetime professional achievement from the Armed Forces Infectious Disease Society. He holds a Bachelor’s Degree in Electrical Engineering from Penn State University, and an M.D. from the University of Pennsylvania.
Chief Financial Officer
Ms. Adams has more than 25 years of experience in accounting and financial management. Before joining Antios, she founded Accounting Concepts, Inc., a firm that provided CFO, accounting and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics, a company that was sold to UCB in 2020. Before that, Ms. Adams was a senior financial executive at Silverstorm Technologies, Inc., where she was responsible for financial and human resources functions and participated in an acquisition of the company by QLogic. Prior, she was the Controller of Starcite, Inc., an internet company, where she was responsible for financial reporting, business model development and internal control systems. Ms. Adams began her career at Ernst & Young, LLP, as a Senior Auditor specializing in entrepreneurial services, and later at Goldman Sachs as a Senior Accounting Officer.
Ms. Adams earned her B.S. in Accounting at State University of New York, Albany and is a certified public accountant in New York.
Katie Laessig, MD
Senior Vice President, Global Regulatory Affairs
Dr. Laessig has more than 20 years of experience in pharmaceutical regulatory roles both in industry and for the U.S. FDA. Before joining Antios, she served as Vice President, Therapeutic Strategy, Strategic Drug Development at IQVIA where she delivered strategic regulatory and clinical development planning for pharmaceuticals and biologics, including support for regulatory interactions, across a range of therapeutic areas for the IQVIA’s biotechnology and pharmaceutical customers. Before that, she was SVP, Regulatory Affairs, Medical Safety and Quality Assurance at RRD International, LLC, where she provided strategic and tactical regulatory, clinical, and development evaluation and direction to product development programs undertaken by RRD for its client companies. From 1999 to 2015, Dr. Laessig served in multiple roles of increasing responsibility at the U.S. FDA including Medical Review Officer and Medical Team Leader, Division of Antiviral Products, and Deputy Director, Division of Anti-Infective Products. From 2000-2016, she volunteered once weekly at the Whitman Walker Clinic in Washington, DC, the city’s largest provider of HIV/AIDS care.
Dr. Laessig earned her M.D. from the University of Maryland School of Medicine and a B.A. in Biology from Cornell University.
Senior Vice President, Clinical Operations
Ms. Fusaro spent more than 20 years managing and leading execution of clinical trials from Phase 1 through Phase 3 in several therapeutic areas including infectious disease. Prior to joining Antios, she held several positions of increasing responsibility at Melinta Therapeutics where she oversaw all clinical, regulatory and pharmacovigilance activities for four antibiotic programs. Before that, she was responsible for clinical operations and clinical project management at The Medicines Company and contributed to the U.S. Food and Drug Administration (FDA) approvals of two antibiotics, ORBACTIV® and VABOMERE®. Additional experience included managing global clinical development of diabetes and cardiovascular programs at Novartis and managing global clinical trials for neuropathic pain, HIV, liver fibrosis and migraine candidates for GlaxoSmithKline.
Ms. Fusaro earned a B.A. in Psychology from State University of New York at Binghamton.
Mark Lockwood, PhD
Director, Process Research and Manufacturing
Dr. Lockwood has 20+ years of experience in the pharmaceutical industry in both process and medicinal chemistry. He began his pharmaceutical career at Abbott Laboratories, where he was part of the process chemistry group responsible for bringing Kaletra to market. He moved from large pharma to be a part of several startup biotech companies in the Atlanta area, including Somatacor Pharmaceuticals, Atherogenics, Metastatix and the Emory Institute for Drug Development, where he developed a process for the manufacture of Molnupiravir, an antivral drug licensed to Ridgeback (and later Merck). Molnupiravir is currently in phase 2/3 clinical trials for the treatment of COVID-19. Dr. Lockwood is currently Director of Process Research and Manufacturing at Antios Therapeutics and is the coauthor on numerous scientific publications and patents.
Dr. Lockwood received his PhD from Purdue University and was a post-doctoral associate at the University of Washington.
Katherine Squires, PhD
Director, Research and Development
Dr. Squires started as a Research and Development Project Manager at Antios before her current position as Director of Research and Development. Prior to joining Antios, she served as an Associate Project Manager at Q2 Solutions, where she managed over $43 million in Phase I-III clinical trial startup projects and led global project teams through the design phase of study-specific databases. During Dr. Squires’ time at Emory University as a Ph.D. student and Laboratory Researcher, she managed molecular genetics projects, authored 10 publications and collaborated with leading research teams across the Southeast, resulting in over $800k in new funding. As an undergraduate student, she held a Junior Laboratory Researcher position across 3 summers at the Georgia Institute of Technology and North Carolina State University.
Dr. Squires earned a Ph.D. in Molecular Pharmacology at Emory University and a bachelor’s in Textile Engineering at North Carolina State University. She has volunteered as a member of Emory’s Molecular & Systems Pharmacology Recruitment Committee, facilitating planning of the annual Pharmacology recruitment weekend.